Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Category
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 3 Component(s) Includes a Live Web Event on 02/16/2023 at 2:00 PM (EST)

    Drug-induced nephrotoxicity (DIN) is a major clinical challenge for a variety of marketed drugs belonging to various therapeutic areas. Successful clinical prevention of DIN requires prior knowledge of drug’s mechanism of action coupled with pathogenic mechanisms of renal injury as well as patient- and drug-related risk factors. Recently, significant innovative advances in the identification of novel early biomarkers for DIN have been made. However, they are not beyond limitations. In such scenarios, mathematical modeling and simulation (M&S) may be used as a robust tool to understand and predict DIN in a clinical setting. This presentation highlights some of the recent advancements in mathematical M&S approaches for DIN. An exemplar of the utility of multiscale and translational M&S for combinatorial effects of a DIN with a proposed preventive therapeutic will be showcased.

    2023 ACCP Virtual Journal Club Webinar: A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches - LIVE

    Live webinar: February 16, 2023 from 2:00 - 3:00 PM ET 

    On-demand webinar recording: February 16, 2023 to February 16, 2026

    Why is this article important to your practice? 

    Drug-induced nephrotoxicity (DIN) is a major clinical challenge for a variety of marketed drugs belonging to various therapeutic areas.  Successful clinical prevention of DIN requires prior knowledge of drug’s mechanism of action coupled with pathogenic mechanisms of renal injury as well as patient- and drug-related risk factors. Recently, significant innovative advances in the identification of novel early biomarkers for DIN have been made. However, they are not beyond limitations. In such scenarios, mathematical modeling and simulation (M&S) may be used as a robust tool to understand and predict DIN in a clinical setting. This presentation highlights some of the recent advancements in mathematical M&S approaches for DIN. An exemplar of the utility of multiscale and translational M&S for combinatorial effects of a DIN with a proposed preventive therapeutic will be showcased.

    Target Audience:

     Physicians, Pharmacists, PhDs.

    Learning Objectives

    After completing this activity, the learner will be able to:

    1) Review the various mechanisms of DIN and highlight the associated classes of nephrotoxic drugs;

    2) Describe the current approach to prevention, diagnosis and management of drug-induced nephrotoxicity;

    3) Summarize recent advances in the role of mathematical M&S in DIN.

    Sihem Bihorel, PharmD, PhD

    Principal Scientist - Scientific Director

    Merck & Co Inc

    Sihem Bihorel is currently a Principal Scientist (Scientific Director) at Merck & Co Inc. Prior to joining Merck, Sihem was an Assistant Professor at the Coll of Pharmacy at the Univ of Florida. Sihem holds Master's degrees in Immunology and in Pharmacometrics, a PharmD and a PhD. Following her PhD research conducted in the Dept of Pharmaceutical Sciences at SUNY at Buffalo, Sihem pursued a Postdoctoral Associate position, followed by a Research Assistant Professor position in the same department. Her expertise is in the end-to-end application of model-informed drug development with a variety of quantitative approaches and in various therapeutic areas. Sihem has authored numerous scientific publications in international peer-reviewed journals, book chapters and presented her work as posters, talks and webinars at various international conferences. She is also a mentor to many students, postdocs, scholars and scientists in academia, the pharmaceutical industry and the International Society of Pharmacometrics.

  • Contains 8 Component(s), Includes Credits

    The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.

    Registration and Pricing

    The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.

    To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact atruluck@accp1.org  for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.

    Requirements for Credits

    All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated into their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits automatically uploaded to the CPE Monitor.

    CE Expiration 12/31/2026




     

  • Contains 48 Component(s), Includes Credits

    The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.

    Registration and Pricing

    The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.

    To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact KLevy@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.

    Requirements for Credits

    All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated into their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits automatically uploaded to the CPE Monitor.

    CE Expiration 12/31/2025




     

  • Contains 2 Component(s)

    The networking event is uniquely designed to address the career development needs of Early-stage Professionals (ESPs) particularly, provide guidance, mentoring and development of translatable skills while navigating career transition from an individual contributor level to being a first-time manager within an organization. ESPs are highly encouraged to participate in the panel discussion with several distinguished ACCP senior colleagues and learn from their professional journey.

    2022 ACCP Early-stage Professionals Mid-Year Networking: Strategies and Skills For New and Future Managers - On Demand

    Why is this webinar important to you? 

    The networking event is uniquely designed to address the career development needs of Early-stage Professionals (ESPs) particularly, provide guidance, mentoring and development of translatable skills while navigating career transition from an individual contributor level to being a first-time manager within an organization. ESPs are highly encouraged to participate in the panel discussion with several distinguished ACCP senior colleagues and learn from their professional journey.

    Target Audience:

    Students, Trainees & Early-stage Professionals (1 - 10 years in first full-time position).

    Learning Objective:

    After completing this activity, the learner will be able to:

    1. Early-stage Professionals will learn how to navigate the transition from being an individual contributor level to a first-time manager;
    2. Learn how to effectively interact with one’s line management;
    3. Learn how to identify existing gaps in professional development related to people management and how honing one's leadership skills can help others to achieve their potential;
    4. Learn how to develop the key translatable skills in successfully managing in a variety of circumstances, including teams, peers and direct reports.

    Faculty Speakers

    • Dr. Angela James, Vice President, Head of Clinical Pharmacology, MacroGenics Inc
    • Dr. Stacey Tannenbaum, Executive Director, Pharmacometrics US, Astellas Pharma
  • Contains 5 Component(s), Includes Credits

    Presented by: Catherijne AJ Knibbe, PhD, PharmD

    Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children-On Demand

    ACCP Virtual Journal Club Webinars

    Live Webinar: August 10, 2022, 2:00 - 3:00 PM ET

    On Demand: August 10, 2022 to August 10, 2025

    See Handouts tab for Continuing Education information on CME and CPE credits.

    Why is this webinar important to you? 

    There is only limited study into the pharmacodynamics of morphine for postoperative use in children, while the pharmacokinetics of morphine has been studied extensively. The effects of morphine in children after surgery are generally registered using behavior pain scales like the COMFORT-Behavior (COMFORT-B) scale. This scale consists of six behavioral items that quantify pain-associated behavior and symptoms as a proxy for the level of pain, each ranging from 1 (low distress/pain) to 5 (high distress/pain). As such, the total COMFORT-B score ranges from 6 to 30, for which scores of 11 to 16 are clinically aimed for during titration. To quantify the concentration-effect relationship of morphine for postoperative pain in preverbal children between 0 and 3 years of age, we applied Item Response Theory modeling in the pharmacokinetic/pharmacodynamic analysis of COMFORT-B scale data from two previous pediatric clinical studies. Learners that complete this course, will be able to explain the pharmacodynamics of morphine across the pediatric age range.

    Target Audience
    Physicians, Pharmacists, PhDs and Physician Assistants.

    Learning Objectives
    After completing this activity, the learner will be able to: 

    1) Define the target concentration of morphine throughout childhood;

    2) Identify non-responders to morphine up-titration.

    To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.


    Catherijne Knibbe, PhD, PharmD

    Professor

    St Antonius Hosp/Leiden Univ

    Catherijne Knibbe, PharmD, PhD is Professor of Individualized Drug Treatment at the Division of Systems Pharmacology and Pharmacy of the LACDR, Leiden University, and clinical pharmacologist-hospital pharmacist at the Department of Clinical Pharmacy of the St. Antonius Hospital, Nieuwegein, the Netherlands. She also holds a guest appointment at the Erasmus MC, Sophia Childrens Hospital Rotterdam. 

    Dr. Knibbe’s primary research focus is to optimize individualized drug treatment for special patient populations such as neonates and children, the elderly and morbidly obese pediatric and adult patients. To this end, she applies advanced statistical and pharmacometric approaches such as population PKPD modelling and PBPK modelling, to existing or newly derived data. To obtain these data, she has designed and conducted a large number of clinical studies not only within her own institution but also with many collaborating hospitals in Europe and the US, supported by different grant mechanisms. She has successfully supervised 23 PhD students, and currently is supervising 10 PhD students and 3 Post Docs/Assistant Professors. She is a co-author of over 250 international peer-reviewed publications and contributions to books. Catherijne is frequently invited to speak at national and international scientific meetings. In the St. Antonius Hospital, besides being member of the Daily Board, she directs the Clinical Pharmacology training program and  the Hospital Pharmacy training program. In addition she is a clinical pharmacology consultant for the departments of Intensive Care and Anesthesiology. She serves on different national and international committees including the Board of the American College of Clinical Pharmacology. 

    Nothing to disclose. 

  • Contains 10 Component(s)

    The ACCP Fundamentals Tutorials series is designed to provide a "not too technical" overview of clinical pharmacology and is ideal for Students & Trainees or those looking to supplement information not available in your curriculum. Each course is offered as a Live webinar featuring a presentation followed by questions and discussion. The registration fee is $40/Members, $50/Non-members, $20/Student Members and $25/Student Non-member.

    ACCP Fundamentals Tutorials Certificate Program

    On-demand webinar recording: June 22, 2022 to June 22, 2025

    Why is this article important to your practice? 

    The ACCP Fundamentals Tutorials series is designed to provide a "not too technical" overview of clinical pharmacology and is ideal for Students & Trainees or those looking to supplement information not available in your curriculum.

    Target Audience:

    Professionals in academic, pharmaceutical/private sector and regulatory settings involved in drug disposition, clinical pharmacology and pharmacometrics. In addition, Students of graduate and professional doctorate programs.

  • Contains 4 Component(s), Includes Credits

    This clinical webinar will be describing the essentials and applications of clinical pharmacology in opioid-sparing techniques for analgesia with emphasis on local anesthetics and discussing advances and challenges of these techniques in adult and pediatric settings.

    ACCP 2022 Clinical Practice Webinar - Clinical Pharmacology of Non-opioid Analgesia-On Demand

    On-demand webinar recording: May 19, 2022 to May 19, 2025

    Why is this article important to your practice? 

    This clinical webinar will be describing the essentials and applications of clinical pharmacology in opioid-sparing techniques for analgesia with emphasis on local anesthetics and discussing advances and challenges of these techniques in adult and pediatric settings.

    Target Audience: 

    Physicians, Pharmacists, PhDs and healthcare professionals interested in clinical pharmacology.

    Learning Objectives: 

    After completing this activity, the learner will be able to:

    1. Describe the clinical use and mechanisms of action of the most common local anesthetic agents;

    2. Assess contraindications, safety and adverse events of various local anesthetics;

    3. Review pharmacokinetic data and the influence of developmental pharmacology;

    4. Discuss pharmacodynamic differences in response to local anesthesia and modification of pharmacodynamics by additives.


    Claude Abdallah, MD

    Anesthesiologist

    Children's National Health System

    Dr. Abdallah is a Pediatric Anesthesiologist, Associate Professor, at Children's National Health System. Dr. Abdallah joined ACCP in 2013 and was actively involved in the Honors & Award Committee from 2014 – 2016. She then joined the Education Committee in 2016. Dr. Abdallah received an MD from St Joseph's Univ Medical School in Beirut, Lebanon and then received her Master's in Pharmacology from Université de Montréal, Canada. She performed her residency in Anesthesiology at Yale-New Haven Hosp followed by a fellowship in pediatric anesthesia at the Hosp for Sick Children, Toronto, Canada. She has authored several publications in peer reviewed journals, abstracts and presented her research regionally, nationally and internationally at educational and organizational venues. She has been in practice for more than 15 years and has an interest in clinical research and pharmacology. 


    Disclosures:
    Faculty: Claude Abdallah, MD, MSc, Anesthesiologist, Children's National Health System has no relevant financial relationship(s) with ineligible companies to disclose.
    Moderator/Planner: Suneet Shukla, PhD, Senior Pharmacologist, US Food & Drug Administration has no relevant financial relationship(s) with ineligible companies to disclose.
    CE Reviewer: Olanrewaju Okusanya, PharmD, Deputy Division Director, US Food & Drug Administration has no relevant financial relationship(s) with ineligible companies to disclose.

  • Contains 1 Component(s)

    Students, Trainees & Early-stage Professionals are encouraged to attend this event and hear from a diverse background of panelists who will share various elements of their career journeys and pivotal decisions related to mentorship, leadership, academic excellence and networking.

    ACCP Students, Trainees & Early-stage Professionals Webinar: Lead the Way - With the Next STEP in Your Career - ON DEMAND

    On-demand webinar recording: April 21, 2022 to April 21, 2027

    Why is this webinar important to you? 

    Students, Trainees & Early-stage Professionals are encouraged to attend this event and hear from a diverse background of panelists who will share various elements of their career journeys and pivotal decisions related to mentorship, leadership, academic excellence and networking. 

    Target Audience:

    Students, Trainees & Early-stage Professionals.

    Learning Objective:

    After completing this activity, the learner will be able to:

    1. Learn how to establish a network that supports your career over time;
    2. Understand the importance of strategically developing a team of mentors to support your career growth and know when it's time to give back by serving as a mentor;
    3. Recognize the opportunities to develop skills that foster academic excellence by participation in ACCP-sponsored events; 
    4. Learn how to build leadership skills and influence without authority.
  • Contains 5 Component(s), Includes Credits

    Presented by: Christina R. Chow, PhD, Head of Research, Emerald Lake Safety

    Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment-ON DEMAND

    ACCP Virtual Journal Club Webinars

    On Demand: March 16, 2022 to March 16, 2025

    See Handouts tab for Continuing Education information on CME and CPE credits.

    Why is this webinar important to you? 

    Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia or as adjunctive treatment for major depressive disorder.
    As obesity (body mass index ≥35 kg/m2) has the potential to affect drug pharmacokinetics and is a common comorbidity of both schizophrenia
    and major depressive disorder, it is important to understand changes in brexpiprazole disposition in this population. This study uses a whole-body
    physiologically-based pharmacokinetic (PBPK) model to compare the pharmacokinetics of brexpiprazole in obese and normal-weight (body mass index 18-
    25 kg/m2) individuals known to be cytochrome P450 2D6 extensive metabolizers and poor metabolizers (PMs).

    Target Audience
    Physicians, Pharmacists, PhDs and Physician Assistants.

    Learning Objectives
    After completing this activity, the learner will be able to: 

    1) Explain the relationship between obesity, Brexpiprazole pharmacokinetics  and clinical outcome;
    2) Articulate the relationship between PMs, Brexpiprazole dosing and clinical outcome;
    3) Learn about the PBPK model.

    To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.


    Christina Chow, PhD

    Head of Research

    Emerald Lake Safety

    Christina Chow has spent her entire career in pharmacology research. At Emerald Lake Safety, Dr. Chow leads collaborations with external scholars and researchers on clinical studies and scientific analyses. Before joining the ELS team, Dr. Chow was a Postdoctoral Fellow at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University and a former Visiting Research Specialist at the Research Center for Advanced Science and Technology at The University of Tokyo. Dr. Chow received her PhD in Pharmacology at the University of Illinois at Chicago.

  • Contains 3 Component(s)

    Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib.

    2021 ACCP Virtual Journal Club Webinar: Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics - On Demand

    On-demand webinar recording: December 8, 2021 to December 8, 2024

    Why is this article important to your practice? 

    Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib. 

    Target Audience:

    Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.